CLASS II Drug recall · Reported 28 Nov 2018 · FDA Enforcement Report

Clopidogrel Tablets, USP, 300 mg, 30 ( unit-dose) count recalled

Dr. Reddy's Laboratories is recalling Clopidogrel Tablets, USP, 300 mg, 30 ( unit-dose) count, distributed nationwide in the US. The recall was initiated on 7 Nov 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: T600530, Exp 11/18
NDC55111-671
Quantity recalled4,212 (30-count blister pack)

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0283-2019
FDA event ID
81530
Recalling firm
Dr. Reddy's Laboratories, Princeton, NJ
Manufacturer
Dr.Reddy's Laboratories Limited
Classification
Class II
Status
Terminated
Recall initiated
7 Nov 2018
FDA classified
27 Nov 2018
Reported
28 Nov 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay
Drug class
Blood Thinners

Timeline

7 Nov 2018Recall initiated by company
27 Nov 2018Classified by FDA+20 days
28 Nov 2018Published in enforcement report+1 day

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Clopidogrel Tablets, USP, 300 mg, 30 (5 x 6 unit-dose) count blister pack, Rx only, Manufactured by Dr. Reddy's Laboratories Limited, Srikakulam - 532 409, India, NDC 55111-671-31

Where it was distributed

U.S.A.nationwide

Nationwide

Questions about this recall

Is Clopidogrel Tablets, USP, 300 mg, 30 ( unit-dose) count recalled?

Yes. Dr. Reddy's Laboratories recalled Clopidogrel Tablets, USP, 300 mg, 30 ( unit-dose) count on 7 Nov 2018. The recall is Class II and its status is Terminated. Recall number D-0283-2019.

Why was it recalled?

Failed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.

Which lots are affected?

Lot #: T600530, Exp 11/18

Where was it sold?

U.S.A.nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Dr. Reddy's Laboratories

All 165

Other Clopidogrel Bi recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIClopidogrel Tablets, USP, 300 mg, 30 ( unit-dose) count recalledClopidogrel BisulfateDr. Reddy's LaboratoriesPotency & AssayNationwide